Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro | Zendy

Joseph J. Eron | Zendy; Victoria A. Johnson | Zendy; Debra P. Merrill | Zendy; TingChao Chou | Zendy; Martin Hirsch | Zendy

Open Access

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

Author(s) -

Joseph J. Eron,

Victoria A. Johnson,

Debra P. Merrill,

TingChao Chou,

Martin Hirsch

Publication year - 1992

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.36.7.1559

Subject(s) - zidovudine , zalcitabine , virology , in vitro , nucleoside analogue , cytotoxicity , human immunodeficiency virus (hiv) , biology , lentivirus , virus , viral replication , nucleoside , viral disease , biochemistry

The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research